Open Access
Table 1.
Schemes of chemotherapy for acute forms of myeloid leukemia (scheme “7 + 3”)
| Patient groups | Applied chemotherapy schemes | Analysed drugs, taking into account the form of release |
|---|---|---|
| Patient group No. 1 (follow‐up period ‐ 1.5 years) | Daunorubicin 60 mg mg / m2 per day (1‐3 days) | Daunorubicin lyophil. powder for inj. 20 mg No. 1, Lens‐Pharm (Russia)
Cytosar® lyof. powder for inj. sol. 100 mg (fl.), with solvent in amp. 5 ml, No. 1, "Pfizer Italia" (Italy). |
| Cytarabine ‐ 100 mg / m2 / day (1‐7 days) | ||
| Patient group No. 2 (follow‐up period ‐ 1.5 years) | Daunorubicin 60 mg mg / m2 per day (1‐3 days) | |
| Cytarabine ‐ 200 mg / m2 / day (1‐7 days) |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.